


TAVR for Bicuspid AV: What's Different?

Jung-Min Ahn, MD

Division of Cardiology, University of Ulsan College of Medicine,
Heart Institute, Asan Medical Center, Seoul, Korea

Current Considerations and Future Directions for Clinical Research in Bicuspid AS



Clinical and Anatomical Challenges




Clinical factors

- Patients present at younger age (longer subsequent lifetime with an aortic prosthesis)
- Presence of concomitant aortopathy
- More likely to present with predominant aortic regurgitation or mixed aortic valve disease with insufficient calcification for device anchoring

Anatomic factors


- Larger annuli (sometimes outside the recommended range for treatment with commercial transcatheter heart valves)
- Increased cusp calcification, which is often bulky and asymmetrical, and not infrequently extends into the aortic annulus
- Eccentric, nontubular shape of aortic valve complex (tapered or flared)
- Presence of calcified raphe(s)
- Increased frequency of coronary anomalies (including left-dominant coronary circulation, anomalous coronary takeoffs)
- Longer leaflets with increased frequency of calcified leaflets (predisposing to coronary occlusion with TAVR)
- Increased frequency of horizontal aorta
- Aortic root and ascending aorta dilation

Available Evidence on TAVR in BAV Stenosis




STS/ACC TVT Registry

Sapien 3




JAMA 2019 Jun 11;321(22):2193-2202

Evolut R




JACC CVI 2020 May 23;S1936-8798(20)30763-9

	Year	Number		Age		Male		PVL ≥ Moderate		PPM		Aortic root injury		Major Bleeding		Mortality at 30 days		Stroke at 30 days	
		BAV	TAV	BAV	TAV	BAV	TAV	BAV	TAV	BAV	TAV	BAV	TAV	BAV	TAV	BAV	TAV	BAV	TAV
Hayashida K ⁵⁶	2013	21	208	82.0±7.0	83.2±6.5	12 (57.1%)	111 (53.4%)	0	2 (1.0%)	3 (14.3%)	15 (7.2%)	0	3 (1.4%)	1 (4.8%)	8 (4.3%)	1 (4.8%)	17 (8.2%)	N/A	N/A
Bauer T ²⁷	2014	38	1357	80.7±6.6	81.8±6.2	17 (44.7%)	570 (42.0%)	10 (25%)	204 (15%)	6 (17%)	475 (35%)	1 (2.6%)	5 (0.4%)	N/A	NA	4 (11%)	149 (11%)	0	41 (3%)
Costopoulos C ²⁸	2014	21	447	76.7±7.1	79.8±7.4	12 (57.1%)	212 (47.4%)	0	11 (3%)	3 (14%)	67 (15%)	2 (10%)	N/A	4 (19%)	90 (20%)	3 (16%)	67 (15%)	0%	5 (1.0%)
Kochman J ⁵⁹	2014	28																0	3 (4%)
Liu XB ³¹	2015	15																1 (6.7%)	1 (4.0%)
Watanabe Y ³³	2015	11																N/A	N/A
Arai T ³⁶	2017	10																0	0
Sannino A ³⁶	2017	88																2 (2.3%)	27 (3.7%)
Yoon SH ⁷	2017	546																16 (2.9%)	10 (1.8%)
Liao YB ²¹	2018	87																1 (1.1%)	0
Aalaei-Andabili SH ²⁷	2018	32																2 (6.3%)	3 (3.1%)
De Biase C ³⁸	2018	83																0	1 (0.6%)
Kim WK ³⁹	2018	144																N/A	N/A
Nagaraja V ⁴⁹	2018	359																10 (2.8%)	20 (5.6%)
Xiong TY ²²	2018	67																N/A	N/A
Mangieri A ¹¹	2018	54	658	80±5.3	82.1±4.3	21 (38.9%)	420 (63.9%)	4 (7.4%)	9 (3.1%)	5 (9.2%)	57 (8.6%)	0	0	2 (3.7%)	34 (5.1%)	2 (3.7%)	17 (2.8%)	4 (7.4%)	12 (1.8%)
Tchetche D ⁴²	2019	101	88	78.2±10.1	83.1±5.7	66 (65.3%)	41 (46.6%)	21 (20.8%) ‡	11 (12.5%) ‡	13 (13%)	12 (14%)	N/A	N/A	11 (11%)	4 (4.5%)	0	3 (3.4%)	2 (2%)	0
Makkar RR	2019	2691	2691	73±10	73±11	1623 (60.3%)	1655 (61.5%)	36/1711 (2.1%)	43/1792 (2.4%)	245 (9.1%)	202 (7.5%)	16 (0.6%)	3 (0.1%)	3 (0.1%)†	3 (0.1%)†	70 (2.6%)	67 (2.5%)	65 (2.4%)	43 (1.6%)
Summary estimates		4396	8066	77.3 (75.3-79.3) §	79.0 (77.0-81.0)			OR 1.63 (1.23-2.14) P=0.001	OR 1.14 (0.93-1.40) P=0.22	OR 5.20 (2.46-11.0) P<0.001	OR 0.87 (0.68-1.13), P=0.30	OR 1.20 (0.95-1.52) P=0.13	OR 1.29 (0.86-1.93) P=0.22						





TAVR vs. SAVR in Bicuspid AS

NIS Data-base (USA)



The FinnValve Registry




JACC Cardiovasc Interv . 2019;12(18):1811-1822.

Clinical Research in Cardiology (2021) 110:429–439

SEV vs. BEV


All Cause Mortality

The Bicuspid TAVR Registry



J Am Coll Cardiol 2016;68:1195–205



The BEAT Registry



Circ Cardiovasc Interv. 2020;13:e008714

S3 vs. Evolut R/PRO



The BEAT Registry



Circ Cardiovasc Interv. 2020;13:e008714


Incidence of Bicuspid AV in isolated AVR

584 men and 348 women from USA (Baylor University)




William Roberts, Circulation 2005;111:920-925

Frequency of Bicuspid AV in TAVR Registry




Calcium: Amount And Morphology

ASAN TAVR Registry




Case 1

Total amount of calcium was 65 mm³ (threshold: 850HU). There was only small amount of calcium.




Case 2

Total amount of calcium was 1625 mm³ (threshold: 850HU). Calcium is located at both leaflets.




Case 3

Total amount of calcium was 380 mm³ (threshold: 850HU). Calcified raphe is observed between right and left coronary cusp.




Case 4

Total amount of calcium was 958 mm³ (threshold: 850HU). Calcium is extended to LVOT.



Higher Risk

Calcification Morphology and Outcomes



Severe AV calcification




Higher Aortic Root Injury
Higher PVL


J Am Coll Cardiol. 2020;76(9):1018–30

Spectrum of BAV Disease

Aortic Valve Morphology




Combined Aortopathy




BAV Aortopathy

Risk Aortic Dissection After SAVR



Rate of Ao Dilatation After SAVR



Itagaki S et al. JACC 2015 Jun 9;65(22):2363-9

Kim YG et al. 2012 Dec;98(24):1822-7

Bicuspid aortopathy does not require earlier surgical intervention

Mohammad A. Zafar, MBBS,^a Jinlin Wu, MD,^{a,b} Thais Faggion Vinholo, MD, MSc,^a Yupeng Li, PhD,^{a,c} Dimitra Papanikolaou, MD,^a Hesham Ellauzi, MD,^{a,d} Nicolai P. Ostberg, MS,^a Asanish Kalyanasundaram, MD,^a Paris D. Kalogerakos, MD, PhD,^a Sandip K. Mukherjee, MD,^a Bulat A. Ziganshin, MD, PhD,^{a,e} John A. Rizzo, PhD,^{a,f} and John A. Elefteriades, MD, PhD (hon)^a


ABSTRACT

Objectives: Guidelines for surgical correction of patients with ascending thoracic aortic aneurysm (ATAA) with a bicuspid aortic valve (BAV) have oscillated over the years. In this study, we outline the natural history of the ascending aorta in patients with BAV and trileaflet aortic valve (TAV) ATAA followed over time, to ascertain if their behavior differs and to determine if a different threshold for intervention is required.

Methods: Aortic diameters and long-term complications (ie, adverse aortic events) of 2428 patients (554 BAV and 1874 TAV) with ATAA before operative repair were reviewed. Growth rates, yearly complication rates, event-free survival, and risk of complications as a function of aortic size were calculated. Long-term follow-up and precise cause of death granularity was achieved via a comprehensive 6-pronged approach.

Results: Aortic growth rate in patients with BAV vs TAV ATAA was 0.20 and 0.17 cm/year, respectively ($P = .009$), with the rate increasing with increasing aortic size. Yearly adverse aortic events rates increased with ATAA size and were lower for patients with BAV. The relative risk of adverse aortic events exhibited an exponential increase with aortic diameter. Patients with BAV had a lower all-cause and ascending aorta-specific adverse aortic events hazard. Age-adjusted 10-year event-free survival was significantly better for patients with BAV, and BAV emerged as a protective factor against type A dissection, rupture, and ascending aortic death.

Conclusions: The threshold for surgical repair of ascending aneurysm with BAV should not differ from that of TAV. Prophylactic surgery should be considered at 5.0 cm for patients with TAV (and BAV) at expert centers. (J Thorac Cardiovasc Surg 2023; ■:1-10)



BAV-ATAA patients have better adverse-event-free survival than TAV-ATAA patients.

CENTRAL MESSAGE


The threshold for prophylactic surgical repair of ATAA in the setting of a bicuspid aortic valve should not differ from that of a trileaflet aortic valve-associated ATAA.

PERSPECTIVE

Guidelines for surgical correction of ATAA in the setting of a BAV have ranged from an aggressive sub-5 cm threshold to >5.5 cm. This study outlines natural history of BAV and TAV related ATAAs over time, revealing that the intervention threshold should not differ between groups, and that prophylactic surgery should be considered at 5.0 cm in both groups to afford protec-

THOR

BAV Aortopathy




*JACC 2016 Surgery for Aortic Dilatation in Patients With Bicuspid Aortic Valves

Device Sizing

Sizing according to the landing zone configuration

CP
CLINIQUE
Pasteur



THE STRUCTURAL HEART DISEASE SUMMIT 2018
Transcatheter Valve Therapies (TVT) and LAA/PFO Closure


Cardiovascular
Research Foundation

Device Sizing

Annulus Sizing

S3

Don't Do Oversizing
Too Much




BE “Remodels” the Annulus

Supra-annulus Sizing


Evolute

- Sequential balloon sizing
- Intercommissural distance
 - LIRA method
 - CASPER method




The annulus “remodels” SE


AMC Favors Sapien 3 For Bicuspid AS



Proportion of TAVR for Bicuspid AS




Type of Bicuspid AV




Procedural and In-Hospital Outcomes of TAVR with S3

	Unadjusted cohort			Propensity score-matched cohort		
	Tricuspid (N=915)	Bicuspid (N=125)	p-value	Tricuspid (N=125)	Bicuspid (N=125)	p-value
Pre-balloon valvuloplasty	383 (41.9%)	93 (74.4%)	<0.001	66 (52.8%)	93 (74.4%)	<0.001
Post-balloon valvuloplasty	272 (29.7%)	49 (39.2%)	0.041	40 (32%)	49 (39.2%)	0.291
Procedural death	3 (0.3%)	0 (0.0%)	1.000	0 (0%)	0 (0%)	1.000
Conversion to operation	7 (0.8%)	0 (0.0%)	1.000	1 (0.8%)	0 (0%)	1.000
PPM insertion in-hospital	55 (6.0%)	8 (6.4%)	1.000	6 (4.8%)	8 (6.4%)	0.783
PCC insertion	13 (1.4%)	2 (1.6%)	0.699	3 (2.4%)	2 (1.6%)	1.000
Coronary obstruction	3 (0.3%)	0 (0.0%)	1.000	0 (0%)	0 (0%)	1.000
Annular rupture	2 (0.2%)	0 (0.0%)	1.000	1 (0.8%)	0 (0%)	1.000
PVL ≥ moderate at discharge	8 (0.9%)	5 (4.0%)	0.013	1 (0.8%)	5 (4.0%)	0.213

Clinical Outcomes of TAVR with S3





Initial S3 Oversizing By Calcium Volume




- *Bicuspid AS*
- *Heavy Calcification*
- *High Risk Morphology*



0 % or less Oversizing



Procedural Complications By Calcium Volume




Undersizing is Effective and Safe



Annulus Area
589 mm²




500 mm²




710 mm²



S3 29mm with -3cc Underfill (2% Oversizing)



S3 26mm with 2 cc underfilling (4% Undersizing)



S3 29mm (9% Undersizing)

Severe Calcified AS: Don't Do Oversizing in S3 Implantation

Conclusion

1. Bicuspid AS has distinct clinical and phenotypical characteristics: younger age, more severe AV calcification, and associated aortopathy.
2. The incidence of paravalvular leakage is increased compared to tricuspid aortic valve cohorts undergoing TAVR.
3. Caution should be exercised regarding aortic injury.
4. TAVR for bicuspid AS is not associated with an excess risk of mortality and stroke.
5. S3 implantation on bicuspid AV is not significantly different from S3 implantation on tricuspid AV.
6. However, there is a need to establish criteria for selecting patients with bicuspid AS who can be successfully treated with TAVR, similar to the Echo-Score used for rheumatic MS.